Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
November 01, 2017 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Provides Business and Financial Update
September 13, 2017 07:30 ET
|
Otonomy, Inc.
Actions taken to reduce costs following suspension of OTIVIDEX™ developmentNon-commercial workforce reduced by one-thirdCurrent cash balance expected to fund company into 2020Review underway to...
Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease
August 30, 2017 07:00 ET
|
Otonomy, Inc.
Missed primary endpoint (p value = 0.62) and all key vertigo secondary endpointsCompany to immediately suspend all development activities for OTIVIDEXCompany is also undertaking a review of its...
Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update
August 03, 2017 16:12 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate Update
July 27, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 27, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis Externa
July 18, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes
June 22, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease
June 20, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 20, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting
May 12, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 12, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at the Bank of America Merrill Lynch Health Care Conference
May 10, 2017 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...